NL-OMON24699招募中不适用
Efficacy and safety of eslicarbazepine acetate as therapy in patients with fibromyalgia: a double-blind, randomized, placebo-controlled, parallel-group, multicentre clinical trial.
BIAL - Portela & Ca, S.A.À Av. da Siderurgia Nacional4745 457 S. Mamede do CoronadoPortugalPhone: +351-229866100Fax: +351-229866192http://www.bial.com.0 个研究点目标入组 480 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 480
研究概览
简要总结
/A
入排标准
入选标准
- •Main Inclusion Criteria at V1:
- •1. Patient is male or female, aged 18 or older;
排除标准
- •Main Exclusion Criteria:
- •1. Patient has any of the following: an inflammatory muscle or rheumatologic disease other than FMS; multiple sclerosis; active infections; untreated endocrine disorders; uncontrolled hypo or hyper thyroidism of any type;
研究者
相似试验
招募中
3 期
Efficacy and safety of Eslicarbazepine Acetate (BIA 2-093) as single therapy for patients with newly diagnosed partial-onset seizures - ESL extension studyG40.0G40.1G40.2EpilepsyRBR-93gkd4Instituto de Neurologia de Curitiba
已完成
3 期
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresCTRI/2011/04/001686Bial Portela C SA615
进行中（未招募）
1 期
Eslicarbazepine Acetate (BIA 2-093) as Therapy for Refractory Partial Seizures in Childrechildren and adolescents with refractory partial epileptic seizuresMedDRA version: 14.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2007-001887-55-ATBIAL - Portela & Ca, S.A.315
进行中（未招募）
1 期
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures - open label extension study with eslicarbazepine acetateAdult patients with recently diagnosed partial-onset seizuresMedDRA version: 21.1Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852EUCTR2015-001243-36-ITBIAL-PORTELA & Cª, S.A.207
进行中（未招募）
1 期
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trialEUCTR2007-001887-55-GBBIAL - Portela & Ca, S.A.304